Physician profile
Stephen Tannenbaum
NPI 1780648220
$8,261.12
in general payments reported to CMS, 2019-2025
45 companies · $789 in 2025
The $789 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $575 · 2020: $889 · 2021: $1,044 · 2022: $1,596 · 2023: $1,781 · 2024: $1,586 · 2025: $789.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,155.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $1,868.28 | 2021-2024 | Axonics |
| Janssen Biotech, INC. | $796.84 | 2019-2024 | Erleada |
| Myriad Genetic Laboratories, INC. | $516.15 | 2021-2024 | Prolaris |
| Teleflex LLC | $450.01 | 2022-2024 | Urolift |
| Sumitomo Pharma America, INC. | $391.44 | 2023-2025 | Gemtesa |
| Verity Pharmaceuticals INC. | $389.91 | 2022-2025 | Tlando, Trelstar |
| Procept Biorobotics Corporation | $349.58 | 2022-2025 | Aquabeam System |
| Astellas Pharma US INC | $339.73 | 2019-2023 | Myrbetriq |
| Rochester Medical Corporation | $339.53 | 2020-2021 | |
| Neotract INC. | $333.74 | 2019-2020 | |
| Coloplast Corp | $289.66 | 2020-2022 | |
| Pfizer INC. | $275.66 | 2019-2025 | |
| Endo Pharmaceuticals INC. | $267.33 | 2019-2024 | Xiaflex |
| Urovant Sciences INC | $194.95 | 2021-2022 | |
| Endo USA, INC. | $149.90 | 2024-2025 | Xiaflex |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $147.85 | 2023-2025 | |
| Abbvie INC. | $143.91 | 2020-2023 | Durysta |
| Smith+Nephew, INC. | $131.52 | 2019 | |
| 180 Medical, INC. | $79.71 | 2024-2025 | Gentlecath Glide |
| Boston Scientific Corporation | $76.64 | 2024-2025 | Axonics, Spaceoar Vue System - 10ml |
| Caldera Medical, INC | $71.95 | 2022 | |
| Merck Sharp & Dohme LLC | $64.89 | 2022-2025 | Keytruda, Welireg, Lynparza |
| Tolmar Pharmaceuticals, INC. | $62.56 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $58.46 | 2025 | Adstiladrin |
| Medtronic, INC. | $41.38 | 2024 | Interstim |
| Olympus America INC. | $37.70 | 2024 | Itind System |
| Convatec INC. | $35.02 | 2022 | |
| Ethicon US, LLC | $34.22 | 2019 | |
| Dendreon Pharmaceuticals LLC | $31.68 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $24.02 | 2023 | Lynparza |
| Bluewind Medical | $23.80 | 2025 | Revi |
| Sun Pharmaceutical Industries INC. | $22.57 | 2024 | |
| Laborie Medical Technologies Corp. | $22.02 | 2024 | Optilume Bph Drug Coated Balloon Catheter, Urgent PC Neuromodulation System |
| Novartis Pharmaceuticals Corporation | $21.38 | 2025 | |
| Profound Medical Corp. | $20.07 | 2025 | Tulsa-Pro |
| Clarus Therapeutics INC. | $20.00 | 2021 | |
| Tolmar, INC. | $19.72 | 2025 | Jatenzo, Eligard |
| Becton, Dickinson and Company | $19.00 | 2024 | Bard Urinary Drainage Bag |
| Blue Earth Diagnostics | $16.71 | 2021 | |
| Avadel Specialty Pharmaceuticals, LLC | $16.41 | 2019 | |
| Axogen | $14.99 | 2025 | |
| Angiodynamics, INC. | $14.67 | 2022 | |
| Foundation Medicine, INC. | $13.82 | 2023 | |
| Myovant Sciences INC. | $13.20 | 2021 | |
| Janssen Pharmaceuticals, INC | $8.54 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Tannenbaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.